Company Description
Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company, engages in the development and commercialization of critical care products.
The company's diversified pipeline includes two late-stage product candidates, Mino-Lok and LYMPHIR. The company has enrollment in a Phase 3 pivotal trial of Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections.
Its biologics license application for LYMPHIR, a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma is under review by the FDA.
Its LYMPHIR also received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In addition, the company is developing CITI-002 (Halo-Lido), which is in Phase 2b trial for the relief of hemorrhoids.
The company was founded in 2007 and is headquartered in Cranford, New Jersey.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Leonard L. Mazur |
Contact Details
Address: 11 Commerce Drive, 1st Floor Cranford, New Jersey 07016 United States | |
| Phone | (908) 967-6676 |
| Website | citiuspharma.com |
Stock Details
| Ticker Symbol | CTXR |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001506251 |
| CUSIP Number | 17322U207 |
| ISIN Number | US17322U2078 |
| Employer ID | 27-3425913 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Leonard L. Mazur | Co-Founder, Chief Executive Officer, Chairman and Secretary |
| Myron Z. Holubiak | Co-Founder and Executive Vice Chairman |
| Dr. Myron S. Czuczman M.D. | Executive Vice President and Chief Medical Officer |
| Jaime Bartushak | Chief Business Officer, Chief Financial Officer and Chief Accounting Officer |
| Gary F. Talarico | Executive Vice President of Operations |
| Ilanit Allen | Vice President of Investor Relations and Corporate Communications |
| Dr. Alan Lader Ph.D. | Senior Vice President and Head of Clinical Operations and Quality Assurance |
| Dhananjay G. Wadekar | Senior Vice President of Business Strategy |
| Kelly Creighton Ph.D. | Executive Vice President of Chemistry, Manufacturing and Controls |
| Nikolas Burlew | Executive Vice President of Quality Assurance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 21, 2024 | 8-K | Current Report |
| May 14, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 30, 2024 | 8-K | Current Report |
| Apr 26, 2024 | 424B5 | Filing |
| Apr 5, 2024 | 8-K | Current Report |
| Mar 18, 2024 | 8-K | Current Report |
| Mar 13, 2024 | 8-K | Current Report |
| Mar 1, 2024 | EFFECT | Notice of Effectiveness |